Cubist Systematic Strategies’s Ovid Therapeutics OVID Stock Holding History

Cubist Systematic Strategies’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$113K	Buy	86,652 +82,778	+2,137%	+$71.7K	﹤0.01%	2758
2025 Q2	$1.28K	Buy	+3,874	New	+$1.17K	﹤0.01%	2879
2023 Q2	–	Sell	-5,155	Closed	-$13.3K	–	4088
2023 Q1	$13.3K	Buy	+5,155	New	+$12.2K	﹤0.01%	3698
2022 Q1	–	Sell	-10,604	Closed	-$34K	–	3718
2021 Q4	$34K	Sell	10,604 -6,915	-39%	-$23.7K	﹤0.01%	3348
2021 Q3	$59K	Buy	+17,519	New	+$63.9K	﹤0.01%	2820
2021 Q2	–	Sell	-48,891	Closed	-$197K	–	3046
2021 Q1	$197K	Buy	+48,891	New	+$162K	﹤0.01%	2480
2020 Q4	–	Sell	-19,309	Closed	-$111K	–	2668
2020 Q3	$111K	Sell	19,309 -1,108	-5%	-$7.41K	﹤0.01%	2269
2020 Q2	$150K	Buy	+20,417	New	+$95.5K	﹤0.01%	2120
2020 Q1	–	Sell	-25,991	Closed	-$108K	–	2363
2019 Q4	$108K	Buy	+25,991	New	+$82.1K	﹤0.01%	2179
2019 Q2	–	Sell	-10,343	Closed	-$18K	–	2551
2019 Q1	$18K	Buy	+10,343	New	+$25.9K	﹤0.01%	2172

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cubist Systematic Strategies's OVID Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Ovid Therapeutics (OVID) stake by 2,137% in Q3 2025, buying an estimated $71.7K and bringing the position to 86,652 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2758.

Cubist Systematic Strategies first reported a position in OVID in Q1 2019 and has held it in 10 quarters since. The position peaked at $197K in Q1 2021. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Cubist Systematic Strategies held 86,652 shares of Ovid Therapeutics worth $113K as of Q3 2025.
Cubist Systematic Strategies bought 82,778 Ovid Therapeutics shares in Q3 2025, an estimated $71.7K.
Ovid Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2758 holding.
Cubist Systematic Strategies first reported a position in Ovid Therapeutics in Q1 2019 and has held it in 10 quarters since.
Cubist Systematic Strategies's Ovid Therapeutics position peaked at $197K in Q1 2021.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.